Normal human B lymphocytes require the fulfillment of several distinct biological criteria prior to undergoing a proliferative response. In addition to an obligate antigen specific activation step, necessary for the acquisition of specific growth factor receptors, cells of B lineage require subsequent interaction with a specific growth factor ligand. One ligand responsible for promoting G1 phase cell cycle progression and S phase entry has been termed B cell growth factor. The moiety possessing B cell specific growth factor activity has been shown to be a relatively heat labile trypsin sensitive protein of 12-14 kD with a major isoelectric point of 6.3-6.6. This protein has been shown to possess cellular specificity and functional specificity. Both the biological and biochemical characterization of this important lymphokine would be greatly expedited by the availability of a homogenously purified reagent in relatively abundant supply. We therefore propose to purify the 12-14 kD BCGF moiety to homogeneity and to examine the biological and biochemical characteristics of the purified reagent. We also propose to prepare this growth factor by means of recombinant technology employing the use of both prokaryotic and eukaryotic expression vectors. In addition, both heterotypic and monoclonal antisera will be prepared against the 12-14 kD protein which should provide an important component for both affinity based purification and for multiple biological investigations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA045148-03
Application #
3482582
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1986-09-01
Project End
1988-11-30
Budget Start
1988-02-26
Budget End
1988-11-30
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Roger Williams Hospital
Department
Type
DUNS #
City
Providence
State
RI
Country
United States
Zip Code
02908
Morgan, J W; Morgan, D M; Lasky, S R et al. (1996) Requirements for induction of vitamin D-mediated gene regulation in normal human B lymphocytes. J Immunol 157:2900-8
Shrayer, D; Bogaars, H; Hearing, V J et al. (1995) Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine. Cancer Immunol Immunother 40:277-82
Takeda, A; Maizel, A L; Kitamura, K et al. (1994) Molecular cloning of the CD45-associated 30-kDa protein. J Biol Chem 269:2357-60
Ohta, T; Kitamura, K; Maizel, A L et al. (1994) Alterations in CD45 glycosylation pattern accompanying different cell proliferation states. Biochem Biophys Res Commun 200:1283-9
Shrayer, D; Koness, J; Kouttab, N et al. (1993) Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model. J Surg Oncol 52:142-9
Shrayer, D; Kouttab, N; Maizel, A et al. (1993) Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Int J Cancer 53:696-702
Takeda, A; Wu, J J; Maizel, A L (1992) Evidence for monomeric and dimeric forms of CD45 associated with a 30-kDa phosphorylated protein. J Biol Chem 267:16651-9
Takeda, A; Maizel, A L (1990) An unusual form of lipid linkage to the CD45 peptide. Science 250:676-9
Flescher, E; Fossum, D; Ballester, A et al. (1990) Characterization of B cell growth in systemic lupus erythematosus. Effects of recombinant 12-kDa B cell growth factor, interleukin 4 and transforming growth factor-beta. Eur J Immunol 20:2425-30
Kumar, A; Vasquez, A; Maizel, A L et al. (1990) Human BCGF-12kD functions as an autocrine growth factor in transformed B cells. Eur Cytokine Netw 1:109-13

Showing the most recent 10 out of 15 publications